{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T08:39:05Z","timestamp":1793090345633,"version":"4.5.0"},"reference-count":101,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T00:00:00Z","timestamp":1787443200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.critrevonc.2026.105556","type":"journal-article","created":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T15:23:09Z","timestamp":1787325789000},"page":"105556","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["CAR-T Cell Therapy for Glioblastoma: Obstacles and Advances"],"prefix":"10.1016","volume":"227","author":[{"given":"Lin","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenwei","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2026.105556_bib1","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1158\/2326-6066.CIR-18-0466","article-title":"IL15 Enhances CAR-T Cell Antitumor Activity by Reducing mTORC1 Activity and Preserving Their Stem Cell Memory Phenotype","volume":"7","author":"Alizadeh","year":"2019","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.critrevonc.2026.105556_bib2","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1038\/s41698-025-01170-7","article-title":"CAR-macrophages in solid tumors: promise, progress, and prospects","volume":"9","author":"Alrehaili","year":"2025","journal-title":"npj Precis. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105556_bib3","doi-asserted-by":"crossref","first-page":"2778","DOI":"10.1038\/s41591-025-03745-0","article-title":"Intracerebroventricular bivalent CAR T cells targeting EGFR and IL-13R\u03b12 in recurrent glioblastoma: a phase 1 trial","volume":"31","author":"Bagley","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.critrevonc.2026.105556_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.neo.2022.100801","article-title":"Spatial organization of heterogeneous immunotherapy target antigen expression in high-grade glioma","volume":"30","author":"Barish","year":"2022","journal-title":"Neoplasia"},{"key":"10.1016\/j.critrevonc.2026.105556_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.carbpol.2023.121081","article-title":"Hyaluronic acid: More than a carrier, having an overpowering extracellular and intracellular impact on cancer","volume":"317","author":"Bhattacharyya","year":"2023","journal-title":"Carbohydr. Polym."},{"key":"10.1016\/j.critrevonc.2026.105556_bib6","doi-asserted-by":"crossref","first-page":"5729","DOI":"10.4049\/jimmunol.160.12.5729","article-title":"Macrophage-derived nitric oxide regulates T cell activation via reversible disruption of the Jak3\/STAT5 signaling pathway","volume":"160","author":"Bingisser","year":"1998","journal-title":"J. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105556_bib7","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1056\/NEJMoa1610497","article-title":"Regression of glioblastoma after chimeric antigen receptor T-cell therapy","volume":"375","author":"Brown","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105556_bib8","doi-asserted-by":"crossref","first-page":"4062","DOI":"10.1158\/1078-0432.CCR-15-0428","article-title":"Bioactivity and safety of IL13R\u03b12-redirected chimeric antigen receptor CD8+ T cells in patients with recurrent glioblastoma","volume":"21","author":"Brown","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105556_bib9","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1038\/s41591-024-02875-1","article-title":"Locoregional delivery of IL-13R\u03b12-targeting CAR-T cells in recurrent high-grade glioma: a phase 1 trial","volume":"30","author":"Brown","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.critrevonc.2026.105556_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2024.105266","article-title":"Advancements and challenges in developing in vivo CAR T cell therapies for cancer treatment","volume":"106","author":"Bui","year":"2024","journal-title":"EBioMedicine"},{"key":"10.1016\/j.critrevonc.2026.105556_bib11","doi-asserted-by":"crossref","first-page":"343re2","DOI":"10.1126\/scitranslmed.aaf6086","article-title":"Clinical trial of blood-brain barrier disruption by pulsed ultrasound","volume":"8","author":"Carpentier","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.critrevonc.2026.105556_bib12","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1038\/ni.3415","article-title":"Emerging concepts of T cell metabolism as a target of immunotherapy","volume":"17","author":"Chang","year":"2016","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105556_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2023.122052","article-title":"Metformin-containing hydrogel scaffold to augment CAR-T therapy against post-surgical solid tumors","volume":"295","author":"Chao","year":"2023","journal-title":"Biomaterials"},{"key":"10.1016\/j.critrevonc.2026.105556_bib14","doi-asserted-by":"crossref","DOI":"10.1148\/rycan.2021200062","article-title":"Assessing oximetry response to chimeric antigen receptor T-cell therapy against glioma with 19F MRI in a murine model","volume":"3","author":"Chapelin","year":"2021","journal-title":"Radiol. Imaging Cancer"},{"key":"10.1016\/j.critrevonc.2026.105556_bib15","article-title":"Enhanced anti-tumor efficacy of \u201cIL-15 and CCL19\u201d -secreting CAR-T cells in human glioblastoma orthotopic xenograft model","volume":"15","author":"Chen","year":"2025","journal-title":"Front. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105556_bib16","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1038\/s41586-019-0985-x","article-title":"NR4A transcription factors limit CAR T cell function in solid tumours","volume":"567","author":"Chen","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2026.105556_bib17","doi-asserted-by":"crossref","first-page":"5983","DOI":"10.3390\/cancers14235983","article-title":"Efficacy, safety, and challenges of CAR T-cells in the treatment of solid tumors","volume":"14","author":"Chen","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2026.105556_bib18","article-title":"Nanoengineered CAR-T Biohybrids for Solid Tumor Immunotherapy with Microenvironment Photothermal-Remodeling Strategy","volume":"17","author":"Chen","year":"2021","journal-title":"Small"},{"key":"10.1016\/j.critrevonc.2026.105556_bib19","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abe7378","article-title":"SynNotch-CAR T cells overcome challenges of specificity, heterogeneity, and persistence in treating glioblastoma","volume":"13","author":"Choe","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.critrevonc.2026.105556_bib20","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1336476","article-title":"Understanding the glioblastoma tumor microenvironment: leveraging the extracellular matrix to increase immunotherapy efficacy","volume":"15","author":"Collado","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105556_bib21","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003351","article-title":"Epitope spreading driven by the joint action of CART cells and pharmacological STING stimulation counteracts tumor escape via antigen-loss variants","volume":"9","author":"Conde","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105556_bib22","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1579925","article-title":"Checkpoint antibody receptor modified ARMed CAR T circumvents the suppressive immunome in GBM","volume":"16","author":"Cook","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105556_bib23","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1186\/s12967-023-04292-3","article-title":"Harnessing the potential of CAR-T cell therapy: progress, challenges, and future directions in hematological and solid tumor treatments","volume":"21","author":"Dagar","year":"2023","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.critrevonc.2026.105556_bib24","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s13045-021-01102-5","article-title":"The relationship between expression of PD-L1 and HIF-1\u03b1 in glioma cells under hypoxia","volume":"14","author":"Ding","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105556_bib25","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/ni1102-991","article-title":"Cancer immunoediting: from immunosurveillance to tumor escape","volume":"3","author":"Dunn","year":"2002","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105556_bib26","doi-asserted-by":"crossref","first-page":"215ra172","DOI":"10.1126\/scitranslmed.3006597","article-title":"PD-1- and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses","volume":"5","author":"Fedorov","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.critrevonc.2026.105556_bib27","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2519819123","article-title":"Synthetic SIGLEC9-based chimeric switch receptor augments the efficacy of CAR macrophages against glioblastoma","volume":"123","author":"Fu","year":"2026","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.critrevonc.2026.105556_bib28","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1097\/NEN.0000000000000183","article-title":"Increase in both CD14-positive and CD15-positive myeloid-derived suppressor cell subpopulations in the blood of patients with glioma but predominance of CD15-positive myeloid-derived suppressor cells in glioma tissue","volume":"74","author":"Gielen","year":"2015","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.critrevonc.2026.105556_bib29","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s11060-020-03483-y","article-title":"Immune suppression in gliomas","volume":"151","author":"Grabowski","year":"2021","journal-title":"J. Neurooncol."},{"key":"10.1016\/j.critrevonc.2026.105556_bib30","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.jtct.2022.03.006","article-title":"Clinical presentation, risk factors, and outcomes of immune effector cell-associated neurotoxicity syndrome following chimeric antigen receptor t cell therapy: a systematic review","volume":"28","author":"Grant","year":"2022","journal-title":"Transplant. Cell. Ther."},{"key":"10.1016\/j.critrevonc.2026.105556_bib31","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1016\/j.cell.2024.03.029","article-title":"Integrative spatial analysis reveals a multi-layered organization of glioblastoma","volume":"187","author":"Greenwald","year":"2024","journal-title":"Cell"},{"key":"10.1016\/j.critrevonc.2026.105556_bib32","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abn8264","article-title":"Delivery of CAR-T cells in a transient injectable stimulatory hydrogel niche improves treatment of solid tumors","volume":"8","author":"Grosskopf","year":"2022","journal-title":"Sci. Adv."},{"key":"10.1016\/j.critrevonc.2026.105556_bib33","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1563303","article-title":"Impact of lactate on immune cell function in the tumor microenvironment: mechanisms and therapeutic perspectives","volume":"16","author":"Gu","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105556_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.icheatmasstransfer.2025.108895","article-title":"Advances and applications of hyperthermia in tumor therapy: mechanisms, techniques, and clinical integration","volume":"164","author":"Gu","year":"2025","journal-title":"Int. Commun. Heat. Mass. Transf."},{"key":"10.1016\/j.critrevonc.2026.105556_bib35","doi-asserted-by":"crossref","first-page":"8021","DOI":"10.1038\/s41467-024-52329-y","article-title":"Ultrasound frequency-controlled microbubble dynamics in brain vessels regulate the enrichment of inflammatory pathways in the blood-brain barrier","volume":"15","author":"Guo","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.critrevonc.2026.105556_bib36","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/s12668-025-02144-6","article-title":"Superparamagnetic iron oxide nanoparticles: multifunctional targeted platforms for cancer detection and combination therapy","volume":"15","author":"Haider","year":"2025","journal-title":"BioNanoScience"},{"key":"10.1016\/j.critrevonc.2026.105556_bib37","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1158\/2159-8290.CD-23-0101","article-title":"Programming CAR T cell tumor recognition: tuned antigen sensing and logic gating","volume":"13","author":"Hamieh","year":"2023","journal-title":"Cancer Discov."},{"key":"10.1016\/j.critrevonc.2026.105556_bib38","doi-asserted-by":"crossref","first-page":"137","DOI":"10.3390\/molecules27010137","article-title":"Roles of the CXCL8-CXCR1\/2 axis in the tumor microenvironment and immunotherapy","volume":"27","author":"Han","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.critrevonc.2026.105556_bib39","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s12987-022-00342-y","article-title":"Application of blood brain barrier models in pre-clinical assessment of glioblastoma-targeting CAR-T based immunotherapies","volume":"19","author":"Huang","year":"2022","journal-title":"Fluids Barriers CNS"},{"key":"10.1016\/j.critrevonc.2026.105556_bib40","doi-asserted-by":"crossref","first-page":"742","DOI":"10.21147\/j.issn.1000-9604.2025.05.07","article-title":"Advances in integrating biomaterials with CAR-T cells for enhancing solid tumor therapy","volume":"37","author":"Huang","year":"2025","journal-title":"Chin. J. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105556_bib41","doi-asserted-by":"crossref","first-page":"7090","DOI":"10.7150\/thno.114257","article-title":"Overcoming barriers in glioblastoma: The potential of CAR T cell immunotherapy","volume":"15","author":"Ijaz","year":"2025","journal-title":"Theranostics"},{"key":"10.1016\/j.critrevonc.2026.105556_bib42","article-title":"In-vivo B-cell maturation antigen CAR T-cell therapy for relapsed or refractory multiple myeloma","volume":"406","author":"J","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2026.105556_bib43","doi-asserted-by":"crossref","DOI":"10.1126\/science.abm5214","article-title":"Distinct myeloid-derived suppressor cell populations in human glioblastoma","volume":"387","author":"Jackson","year":"2025","journal-title":"Science"},{"key":"10.1016\/j.critrevonc.2026.105556_bib44","doi-asserted-by":"crossref","first-page":"4016","DOI":"10.1038\/s41467-019-11869-4","article-title":"CXCR1- or CXCR2-modified CAR T cells co-opt IL-8 for maximal antitumor efficacy in solid tumors","volume":"10","author":"Jin","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.critrevonc.2026.105556_bib45","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aag2196","article-title":"Reporter gene imaging of targeted T cell immunotherapy in recurrent glioma","volume":"9","author":"Keu","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.critrevonc.2026.105556_bib46","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1158\/1078-0432.CCR-20-2400","article-title":"Modification of extracellular matrix enhances oncolytic adenovirus immunotherapy in glioblastoma","volume":"27","author":"Kiyokawa","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105556_bib47","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/j.trecan.2025.08.009","article-title":"Overcoming solid-tumor barriers: armored CAR-T cell therapy","volume":"11","author":"Kwon","year":"2025","journal-title":"Trends Cancer"},{"key":"10.1016\/j.critrevonc.2026.105556_bib48","doi-asserted-by":"crossref","first-page":"3259","DOI":"10.1158\/1078-0432.CCR-18-3034","article-title":"Comparison of biomarker assays for EGFR: implications for precision medicine in patients with glioblastoma","volume":"25","author":"Lassman","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105556_bib49","doi-asserted-by":"crossref","first-page":"3522","DOI":"10.1016\/j.ymthe.2024.07.020","article-title":"Armored bicistronic CAR T cells with dominant-negative TGF-\u03b2 receptor II to overcome resistance in glioblastoma","volume":"32","author":"Li","year":"2024","journal-title":"Mol. Ther."},{"key":"10.1016\/j.critrevonc.2026.105556_bib50","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1146\/annurev.immunol.24.021605.090737","article-title":"Transforming growth factor-beta regulation of immune responses","volume":"24","author":"Li","year":"2006","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105556_bib51","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2024.122871","article-title":"Enhancing CAR-T cell therapy against solid tumor by drug-free triboelectric immunotherapy","volume":"314","author":"Li","year":"2025","journal-title":"Biomaterials"},{"key":"10.1016\/j.critrevonc.2026.105556_bib52","article-title":"Immunoregulatory hydrogel-fiber composite device as a local T cell activator for inhibiting glioblastoma recurrence","volume":"1","author":"Li","year":"2025","journal-title":"Cell. Biomater."},{"key":"10.1016\/j.critrevonc.2026.105556_bib53","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1016\/j.cell.2025.02.035","article-title":"Engineering sonogenetic EchoBack-CAR T cells","volume":"188","author":"Liu","year":"2025","journal-title":"Cell"},{"key":"10.1016\/j.critrevonc.2026.105556_bib54","article-title":"CAR-T cells locally delivered in porcine decellularized matrix hydrogels enhance survival in post-resection glioblastoma","author":"Logun","year":"2025","journal-title":"bioRxiv"},{"key":"10.1016\/j.critrevonc.2026.105556_bib55","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO classification of tumors of the central nervous system: a summary","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.critrevonc.2026.105556_bib56","doi-asserted-by":"crossref","first-page":"3148","DOI":"10.1016\/j.cell.2023.06.002","article-title":"Vaccine-boosted CAR T crosstalk with host immunity to reject tumors with antigen heterogeneity","volume":"186","author":"Ma","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.critrevonc.2026.105556_bib57","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2025.114609","article-title":"CAR-T cell therapies are coming after glioblastoma: an overview of early phase clinical trials and future perspectives","volume":"29","author":"Mariniello","year":"2026","journal-title":"iScience"},{"key":"10.1016\/j.critrevonc.2026.105556_bib58","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105556_bib59","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009110","article-title":"Preclinical evaluation of antigen-sensitive B7-H3-targeting nanobody-based CAR-T cells in glioblastoma cautions for on-target, off-tumor toxicity","volume":"12","author":"Meeus","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105556_bib60","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2025.114168","article-title":"situ formed chemo-immunotherapeutic hydrogel for suppression of postoperative glioma recurrence and intraoperative hemostasis","volume":"387","author":"Meng","year":"2025","journal-title":"J. Control. Release"},{"key":"10.1016\/j.critrevonc.2026.105556_bib61","doi-asserted-by":"crossref","first-page":"737","DOI":"10.3389\/fimmu.2020.00737","article-title":"The emerging role of myeloid-derived suppressor cells in the glioma immune suppressive microenvironment","volume":"11","author":"Mi","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105556_bib62","doi-asserted-by":"crossref","first-page":"726","DOI":"10.3390\/cells13090726","article-title":"A roadmap of CAR-T-cell therapy in glioblastoma: challenges and future perspectives","volume":"13","author":"Montoya","year":"2024","journal-title":"Cells"},{"key":"10.1016\/j.critrevonc.2026.105556_bib63","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1038\/s41551-025-01415-7","article-title":"PET-based tracking of CAR T cells and viral gene transfer using a cell surface reporter that binds to lanthanide complexes","volume":"9","author":"Morath","year":"2025","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.critrevonc.2026.105556_bib64","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1200\/JCO.19.02104","article-title":"Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: results from the US lymphoma CAR T consortium","volume":"38","author":"Nastoupil","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105556_bib65","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.cell.2019.06.024","article-title":"An integrative model of cellular states, plasticity, and genetics for glioblastoma","volume":"178","author":"Neftel","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.critrevonc.2026.105556_bib66","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaa0984","article-title":"A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma","volume":"9","author":"O\u2019Rourke","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.critrevonc.2026.105556_bib67","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abg5841","article-title":"Fibrin gel enhances the antitumor effects of chimeric antigen receptor T cells in glioblastoma","volume":"7","author":"Ogunnaike","year":"2021","journal-title":"Sci. Adv."},{"key":"10.1016\/j.critrevonc.2026.105556_bib68","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.semcancer.2012.01.011","article-title":"Cross-talk between myeloid-derived suppressor cells (MDSC), macrophages, and dendritic cells enhances tumor-induced immune suppression","volume":"22","author":"Ostrand-Rosenberg","year":"2012","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.critrevonc.2026.105556_bib69","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-008429","article-title":"PD-1 downregulation enhances CAR-T cell antitumor efficiency by preserving a cell memory phenotype and reducing exhaustion","volume":"12","author":"Ouyang","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105556_bib70","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1038\/ni1536","article-title":"CD4+CD25+Foxp3+ regulatory T cells induce cytokine deprivation-mediated apoptosis of effector CD4+ T cells","volume":"8","author":"Pandiyan","year":"2007","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105556_bib71","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009604","article-title":"Novel tri-specific T-cell engager targeting IL-13R\u03b12 and EGFRvIII provides long-term survival in heterogeneous GBM challenge and promotes antitumor cytotoxicity with patient immune cells","volume":"12","author":"Park","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105556_bib72","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1016\/j.ymthe.2025.03.005","article-title":"From concept to cure: The evolution of CAR-T cell therapy","volume":"33","author":"Patel","year":"2025","journal-title":"Mol. Ther."},{"key":"10.1016\/j.critrevonc.2026.105556_bib73","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1170153","article-title":"Physiological fibrin hydrogel modulates immune cells and molecules and accelerates mouse skin wound healing","volume":"14","author":"Pereira","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105556_bib74","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1093\/neuonc\/nor042","article-title":"Myeloid-derived suppressor cell accumulation and function in patients with newly diagnosed glioblastoma","volume":"13","author":"Raychaudhuri","year":"2011","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.critrevonc.2026.105556_bib75","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1084\/jem.20050715","article-title":"Arginase I in myeloid suppressor cells is induced by COX-2 in lung carcinoma","volume":"202","author":"Rodriguez","year":"2005","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.critrevonc.2026.105556_bib76","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.ado9511","article-title":"A cross-talk established by tumor-targeted cytokines rescues CAR T cell activity and engages host T cells against glioblastoma in mice","volume":"17","author":"Rossari","year":"2025","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.critrevonc.2026.105556_bib77","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.cell.2016.09.011","article-title":"Engineering T cells with customized therapeutic response programs using synthetic notch receptors","volume":"167","author":"Roybal","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.critrevonc.2026.105556_bib78","doi-asserted-by":"crossref","first-page":"4325","DOI":"10.1158\/1078-0432.CCR-20-3760","article-title":"Opening of the blood-brain barrier using low-intensity pulsed ultrasound enhances responses to immunotherapy in preclinical glioma models","volume":"27","author":"Sabbagh","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105556_bib79","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1016\/j.trecan.2022.06.008","article-title":"Therapeutic targeting of regulatory T cells in cancer","volume":"8","author":"Shan","year":"2022","journal-title":"Trends Cancer"},{"key":"10.1016\/j.critrevonc.2026.105556_bib80","doi-asserted-by":"crossref","first-page":"A027","DOI":"10.1158\/2326-6074.IO2025-A027","article-title":"Abstract A027: IL-12\/IL-18 armored CAR-T cells drive pro-inflammatory remodeling of the glioblastoma tumor microenvironment","volume":"13","author":"Shih","year":"2025","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.critrevonc.2026.105556_bib81","doi-asserted-by":"crossref","DOI":"10.1126\/science.adl4237","article-title":"Programming tissue-sensing T cells that deliver therapies to the brain","volume":"386","author":"Simic","year":"2024","journal-title":"Science"},{"key":"10.1016\/j.critrevonc.2026.105556_bib82","doi-asserted-by":"crossref","unstructured":"Stupp, R., Mason, W.P., van den Bent, M.J., Weller, M., Fisher, B., Taphoorn, M.J.B., Belanger, K., Brandes, A.A., Marosi, C., Bogdahn, U., Curschmann, J., Janzer, R.C., Ludwin, S.K., Gorlia, T., Allgeier, A., Lacombe, D., Cairncross, J.G., Eisenhauer, E., Mirimanoff, R.O. (n.d) European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups, National Cancer Institute of Canada Clinical Trials Group, 2005. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352, 987\u2013996. https:\/\/doi.org\/10.1056\/NEJMoa043330.","DOI":"10.1056\/NEJMoa043330"},{"key":"10.1016\/j.critrevonc.2026.105556_bib83","first-page":"299","article-title":"Management of glioblastoma: State of the art and future directions","volume":"70","author":"Tan","year":"2020","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.critrevonc.2026.105556_bib84","article-title":"Heat-inducible CAR-T overcomes adverse mechanical tumor microenvironment in a 3D bioprinted glioblastoma model","volume":"26","author":"Tang","year":"2024","journal-title":"Mater. Today Bio"},{"key":"10.1016\/j.critrevonc.2026.105556_bib85","doi-asserted-by":"crossref","first-page":"v345","DOI":"10.1093\/neuonc\/noaf201.1364","article-title":"EXTH-30. Improving intravenous B7-H3 CAR T cell treatment for DMG using MRgFUS","volume":"27","author":"Teis","year":"2025","journal-title":"Neuro-Oncol."},{"key":"10.1016\/j.critrevonc.2026.105556_bib86","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s13073-025-01514-9","article-title":"SCAN-ACT: adoptive T cell therapy target discovery through single-cell transcriptomics","volume":"17","author":"Testa","year":"2025","journal-title":"Genome Med."},{"key":"10.1016\/j.critrevonc.2026.105556_bib87","doi-asserted-by":"crossref","first-page":"2656","DOI":"10.1021\/bm500502n","article-title":"Thermoreversible poly(ethylene glycol)-g-chitosan hydrogel as a therapeutic T lymphocyte depot for localized glioblastoma immunotherapy","volume":"15","author":"Tsao","year":"2014","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.critrevonc.2026.105556_bib88","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.actbio.2021.06.009","article-title":"Cancer cell migration in collagen-hyaluronan composite extracellular matrices","volume":"130","author":"Unnikandam Veettil","year":"2021","journal-title":"Acta Biomater."},{"key":"10.1016\/j.critrevonc.2026.105556_bib89","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s13045-025-01744-9","article-title":"Challenges and limitations of chimeric antigen receptor T-cell therapies in solid tumors: why are approvals restricted to hematologic malignancies?","volume":"18","author":"Vo","year":"2025","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105556_bib90","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1038\/nri1901","article-title":"The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design","volume":"6","author":"Waldmann","year":"2006","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105556_bib91","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2025-012308","article-title":"Chimeric antigen receptor (CAR) T-cell therapy for glioblastoma (GBM): current clinical insights, challenges, and future directions","volume":"13","author":"Walton","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105556_bib92","article-title":"Co-delivery of multiple RNAs via lipid nanoparticles enables precise gene editing of CAR-T cells","volume":"15","author":"Wang","year":"2026","journal-title":"Adv. Healthc. Mater."},{"key":"10.1016\/j.critrevonc.2026.105556_bib93","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1038\/s41392-020-00256-x","article-title":"The model of cytokine release syndrome in CAR T-cell treatment for B-cell non-Hodgkin lymphoma","volume":"5","author":"Wei","year":"2020","journal-title":"Signal. Transduct. Target. Ther."},{"key":"10.1016\/j.critrevonc.2026.105556_bib94","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/S1470-2045(17)30517-X","article-title":"Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial","volume":"18","author":"Weller","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2026.105556_bib95","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1126\/science.abc6270","article-title":"Precise T cell recognition programs designed by transcriptionally linking multiple receptors","volume":"370","author":"Williams","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.critrevonc.2026.105556_bib96","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1097\/RLI.0000000000000946","article-title":"Multimodal in vivo tracking of chimeric antigen receptor T cells in preclinical glioblastoma models","volume":"58","author":"Wu","year":"2023","journal-title":"Invest. Radiol."},{"key":"10.1016\/j.critrevonc.2026.105556_bib97","article-title":"Magnetic hyperthermia in oncology: nanomaterials-driven combinatorial strategies for synergistic therapeutic gains","volume":"33","author":"Xiong","year":"2025","journal-title":"Mater. Today Bio"},{"key":"10.1016\/j.critrevonc.2026.105556_bib98","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s13045-025-01759-2","article-title":"vivo CAR cell therapy: from bench to bedside","volume":"18","author":"Xu","year":"2025","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105556_bib99","article-title":"Cancer-treating-cancer\u201d strategy: entrapping engineered dying cancer cells in immunotherapeutic hydrogel against tumor recurrence","author":"Zhang","year":"2025","journal-title":"Cell. Biomater."},{"key":"10.1016\/j.critrevonc.2026.105556_bib100","doi-asserted-by":"crossref","DOI":"10.26599\/NR.2025.94907359","article-title":"Hyaluronidase nanogel-armed CAR-T cell for synergistically reducing tumor extracellular matrix and improving efficacy against solid tumors","volume":"18","author":"Zhao","year":"2025","journal-title":"Nano Res."},{"key":"10.1016\/j.critrevonc.2026.105556_bib101","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2426724122","article-title":"vivo generation of CAR macrophages via the enucleated mesenchymal stem cell delivery system for glioblastoma therapy","volume":"122","author":"Zhou","year":"2025","journal-title":"Proc. Natl. Acad. Sci. USA"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826004439?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826004439?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T08:03:41Z","timestamp":1793088221000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842826004439"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":101,"alternative-id":["S1040842826004439"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105556","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CAR-T Cell Therapy for Glioblastoma: Obstacles and Advances","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105556","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"105556"}}